Prevest Denpro Reports Strong Sales Growth Amid Mixed Financial Indicators

Prevest Denpro, a microcap player in the healthcare services sector, has recently undergone a financial trend adjustment reflecting its improved performance metrics for the quarter ending March 2025. The company reported its highest net sales at Rs 18.45 crore, alongside a notable PBDIT of Rs 6.54 crore and a profit before tax (PBT) of Rs 6.07 crore. Additionally, the profit after tax (PAT) reached Rs 5.14 crore, translating to an earnings per share (EPS) of Rs 4.28, marking a significant achievement for the company.
However, not all indicators are favorable. The return on capital employed (ROCE) for the half-year stands at a relatively low 22.98%, suggesting areas for improvement in capital efficiency.

In terms of market performance, Prevest Denpro has shown resilience, particularly over the past year, with a stock return of 22.76%, significantly outpacing the Sensex return of 8.17% during the same period. Despite some fluctuations in the short term, the company has demonstrated a strong recovery compared to the broader market, particularly over the last week, where it achieved a return of 3.53% against a slight decline in the Sensex. This performance highlights the company's potential amidst the challenges faced in the healthcare sector.